Class I or class III agents for atrial fibrillation: Are we asking the right question?

PACE - Pacing and Clinical Electrophysiology

Volumn 26, Issue 7 II, 2003, Pages 1613-1619

  Pacifico, Antonio ^a   Henry, Philip D ^a  

^a Texas Arrhythmia Institute   (United States)

Author keywords

Acute and chronic drug effects; Electric remodeling; Ion channel selectivity; Vaughan Williams classification

Indexed keywords

4 AMINOPYRIDINE; ALMOKALANT; AMIODARONE; ANTIARRHYTHMIC AGENT; BENZOTHIADIAZINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOHEXIMIDE; DACTINOMYCIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; ISRADIPINE; LOCAL ANESTHETIC AGENT; NIFEDIPINE; PHENYLALKYLAMINE; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; PRODRUG; PROPAFENONE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; THYROID HORMONE RECEPTOR; VERAPAMIL;

AGE; CARDIOVERSION; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DEFIBRILLATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SELECTIVITY; ELECTROPHYSIOLOGY; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HEART ATRIUM MUSCLE; HEART MUSCLE; HEART MUSCLE POTENTIAL; HEART PROARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HEART RHYTHM; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; META ANALYSIS; MORTALITY; NONHUMAN; POTASSIUM CURRENT; PREDICTION; RECEPTOR DOWN REGULATION; SINUS RHYTHM; TORSADE DES POINTES; TREATMENT OUTCOME;

EID: 0038640793     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2003.t01-1-00240.x     Document Type: Conference Paper

References (48)

1. Mead GE, Flapan AD, Elder AT. Electrical cardioversion for atrial fibrillation and flutter. Cochrane Database Syst Rev 2002; 1:CD002903.
2. Nichol G, McAllister F, Pham B, et al. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 2002; 87:535-543.
3. Echt DS, Liebson PR, Mitchell B, et al. For the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. New Engl J Meal 1991; 324:781-788.
4. Waldo AL Camm AJ, Ruyter H, et al. for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348:7-12.
5. Snyders DJ. Structure and function of cardiac potassium channels. Cardiovasc Res 1999; 42:377-390.
6. Torp-Pedersen C, Moller M, Bloch-Thomson PE, Agner E, Carlsen J, Videboek J, et al. for the Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group (DIAMOND-CHF). Dofetilide in patients with congestive heart failure and left ventricular dysfunction. New Engl J Med 1999; 341:857-865.
7. Zheng ZJ, Croft JB, Giles WH, et al. Sudden cardiac death in the United States, 1989-1998. Circulation 2001; 104:2158-2163.
8. Julian DG, Camm AJ, Frangin Gjanse MJ, et al. for the European Myocardial Infarct Amiodarone Trial Investigators. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349:667-674.
9. Camm JA, Conollaly SJ, Roberts R, et al. for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randemised trial outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349:675-682.
10. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997; 350:1417-1424.
11. Benjamin EJ, Levy D, Vaziri SM, et aI. Independent risk factors for atrial fibrillation in a population-based cohort - The Framingham Study. JAMA 1994; 271:840-844.
12. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96:2425-2461.
13. Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: Morbidity and risk factors. J Intern Mad 2001; 250:382-389.
14. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: Scientific review. JAMA 2002; 287:883-889.
15. Henry PD, Pacifico A. Altering molecular mechanisms to prevent sudden arrhythmic death. Lancet 1998; 351:1276-1278.
16. Nattel S. Effects of ionic remodeling on cardiac antiarrhythmic drug actions. J Cardiovasc Pharmacol 2001; 38:809-811.
17. Catterall WA. Molecular mechanisms of gating and drug block of sodium channels. Novartis Found Symp 2002; 241:206-218.
18. Guo W, Kada K, Kamiya K, et al. IGF-I regulates K(+)-channel expression of cultured neonatal rat ventricular myocyles. Am J Physiol 1997; 277:H2599-25606.
19. Levitan ES, Hershman KM, Sherman TG, et al. Dexamethasone and stress upregulate Kv1.5 K+ channel gene expression in rat ventricular myocytes. Neuropharmacology 1996; 35:1001-1006.
20. Nasir N Jr, Swarna US, Boahene KA, et al. Therapy of sustained ventricular arrhythmias with amiodarone: Prediction of efficacy with serial electrophysiologic studies. Cardiovasc Pharmacol Therapeut 1996; 1:123-132.
21. Kodoma I, Kamiya K, Toyama J. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 1999; 84:20R-28R.
22. Kamiya K, Nishiyama A, Yasui K, et al. Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 2001; 103:1317-1324.
23. Balser JR, Bannet PB, Hondeghem LM, et al. Suppression of time-dependent outward current in guinea pig ventricular myocytes - actions of quinidine and amiodarone. Circ Res 1991; 69:519-529.
24. Lee KS, Lee EW. Ionic mechanism of ibutilide in human atrium: Evidence for a drug-induced Na+ current through a nifedipine inhibited inward channel. J Pharmacol Exp Ther 1998; 286:9-22.
25. Shahrara S, Drvota V. Thyroid hormone alpha1 and beta1 receptor mRNA are downregulated by amiodarone in mouse myocardium. J Cardiovasc Pharmacol 1999; 34:261-267.
26. Drvota V, Blange I, Haggblad J, et al. Desethylamiodarone prolongation of cardiac repolarization is dependent on gene expression: A novel antiarrhythmic mechanism. J Cardiovasc Pharmacol 1998; 32:654-661.
27. Dukes ID, Vaughan Williams EM. The multiple modes of action of propafenone. Eur Heart J 1984; 5:115-125.
28. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84:1831-1851.
29. Lees-Miller JP, Duan J, Teng JQ, et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: Involvement of S6 sites. Molec Pharmacol 2000; 57:367-374.
30. Motoike HK, Bodi I, Schwartz A, et al. A region in the IVS5 of the human cardiac L-type channel is required for the use-dependent block by phenylalkylamines and benzothiazepines. J Biol Chem 1999; 274:9406-9420.
31. Finlayson K, Pennington AJ, Kelly JS. [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel? Eur J Pharmacol 2001; 412:203-212.
32. Slawsky MT, Castle NA. K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. J Pharmacol Exp Ther 1994; 269:66-74.
33. Yamashita T, Nsksjima T, Hamada E, et al. Flecainide inhibits the transient outward current in atrial myocytes. J Pharmacol Exp Ther 1995, 274:315-321.
34. Wang Z, Fermini B, Nattels S. Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier current in human atrial myocytes. J Pharmacol Exp Ther 1995; 272:184-196.
35. Follmer CH, Cullinan CA, TJ. Differential block of cardiac delayed rectifier current by class 1c antiarrhythmic drugs: Evidence for channel block and unblock. Cardiovasc Res 1992; 26:1121-1130.
36. Seki A, Hagiwara N, Kasanuki H. Effects of propafenone on K currents in human atrial myocytes. Br J Pharmacol 1999; 126:1153-1162.
37. Duan D, Fermini B, Nattel S. Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther 1993; 264:1113-1123.
38. Mergenthaler J, Haverkamp W, Huttenhofer A, et al. Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel. Naunyn Schiedebergs Arch Pharmacol 2001; 363:472-480.
39. Gross GJ, Castle NA. Propafenone inhibition of human atrial myocyte repolarizing currents. J Mol Cell Cardiol 1998; 30:783-793.
40. Mjasnikov LA. Symposium on Verapamil, Moscow, Nov 24, 1969. Arzneimittelforschung (Drug Res) 1970; 20 (9a):1277-1356.
41. Henry PD. Comparative pharmacology of calcium antagonists: Nifedipine, verapamil, and diltiazem. Am J Cardiol 1980; 46:1047-1058.
42. Waldegger S, Miemeyer G, Morike K, et al. Effect of verapamil enantiomers and metabolites on cardiac K+ channels expressed in Xenopus oocytes. Cell Physiol Biochem 1999; 9:81-89.
43. Zhang X, Anderson JW, Fedida D. Characterization of nifedipine block of the human heart delayed rectifier, hKv1.5. J Pharmacol Exp Ther 1997; 281:1247-1256.
44. Crystal E, Conolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery. Circulation 2002; 106:75-80.
45. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation (CTAF) Investigators. New Engl J Med 2000; 342:913-920.
46. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation (meta-analysis). J Am Coll Cardiol 2001; 37:542-547.
47. Boriani G, Martignani C, Biffi M, et al. Oral loading with propafenone for conversion of recent-onset atrial fibrillation: A review on in-hospital treatment. Drugs 2002; 62:415-423.
48. Pacifico A, Hohnloser SH, Williams JH, et al. for the d,l Sotalol Implantable Cardioverter-Defibrillator Study Group. Prevention of implantable-defibrillator shocks by treatment with sotalol. New Engl J Med 1999; 340:1855-1862.